Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJK0W9
|
|||
| Drug Name |
NCGC607
|
|||
| Synonyms |
1462267-07-7; MLS003874050; KUC107647N; KUC107647N-02; SMR002530685; 2-[2-(4-iodoanilino)-2-oxoethoxy]-N-[2-(N-methylanilino)-2-oxoethyl]benzamide; 2-(2-((4-iodophenyl)amino)-2-oxoethoxy)-N-(2-(methyl(phenyl)amino)-2-oxoethyl)benzamide; ksc-22-92-D69; SCHEMBL16534468; GTPL10697; EX-A4846; NCGC00241607; NCGC00241607-01; KSC-242-13-2; 2-[2-[(4-Iodophenyl)amino]-2-oxoethoxy]-N-[2-(methylphenylamino)-2-oxoethyl]-benzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gaucher disease [ICD-11: 5C56.0Y; ICD-9: 272.7] | Preclinical | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H22IN3O4
|
|||
| Canonical SMILES |
CN(C1=CC=CC=C1)C(=O)CNC(=O)C2=CC=CC=C2OCC(=O)NC3=CC=C(C=C3)I
|
|||
| InChI |
1S/C24H22IN3O4/c1-28(19-7-3-2-4-8-19)23(30)15-26-24(31)20-9-5-6-10-21(20)32-16-22(29)27-18-13-11-17(25)12-14-18/h2-14H,15-16H2,1H3,(H,26,31)(H,27,29)
|
|||
| InChIKey |
HFVDMJQQAKLUSN-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucosylceramidase (GBA) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Other glycan degradation | |||
| Sphingolipid metabolism | ||||
| Metabolic pathways | ||||
| Lysosome | ||||
| Pathwhiz Pathway | Sphingolipid Metabolism | |||
| Reactome | Glycosphingolipid metabolism | |||
| WikiPathways | Sphingolipid metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A New Glucocerebrosidase Chaperone Reduces alpha-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. J Neurosci. 2016 Jul 13;36(28):7441-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.